FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376130112> ?p ?o ?g. }

• W4376130112 abstract "Purpose In this prospective phase 2 trial, we investigated the toxicity and patient-reported quality-of-life outcomes in patients treated with stereotactic body radiation therapy (SBRT) to the prostate gland and a simultaneous focal boost to magnetic resonance imaging (MRI)–identified intraprostatic lesions while also de-escalating dose to the adjacent organs at risk. Methods and Materials Eligible patients included low- or intermediate-risk prostate cancer (Gleason score ≤7, prostate specific antigen ≤20, T stage ≤2b). SBRT was prescribed to 40 Gy in 5 fractions delivered every other day to the prostate, with any areas of high disease burden (MRI-identified prostate imaging reporting and data system 4 or 5 lesions) simultaneously escalated to 42.5 to 45 Gy and areas overlapping organs at risk (within 2 mm of urethra, rectum, and bladder) constrained to 36.25 Gy (n = 100). Patients without a pretreatment MRI or without MRI-identified lesions were treated to dose of 37.5 Gy with no focal boost (n = 14). Results From 2015 to 2022, a total of 114 patients were enrolled with a median follow-up of 42 months. No acute or late grade 3+ gastrointestinal (GI) toxicity was observed. One patient developed late grade 3 genitourinary (GU) toxicity at 16 months. In patients treated with focal boost (n = 100), acute grade 2 GU and GI toxicity was seen in 38% and 4% of patients, respectively. Cumulative late grade 2+ GU and GI toxicities at 24 months were 13% and 5% respectively. Patient-reported outcomes showed no significant long-term change from baseline in urinary, bowel, hormonal, or sexual quality-of-life scores after treatment. Conclusions SBRT to a dose of 40 Gy to the prostate gland with a simultaneous focal boost up to 45 Gy is well tolerated with similar rates of acute and late grade 2+ GI and GU toxicity as seen in other SBRT regimens without intraprostatic boost. Moreover, no significant long-term changes were seen in patient-reported urinary, bowel, or sexual outcomes from pretreatment baseline. In this prospective phase 2 trial, we investigated the toxicity and patient-reported quality-of-life outcomes in patients treated with stereotactic body radiation therapy (SBRT) to the prostate gland and a simultaneous focal boost to magnetic resonance imaging (MRI)–identified intraprostatic lesions while also de-escalating dose to the adjacent organs at risk. Eligible patients included low- or intermediate-risk prostate cancer (Gleason score ≤7, prostate specific antigen ≤20, T stage ≤2b). SBRT was prescribed to 40 Gy in 5 fractions delivered every other day to the prostate, with any areas of high disease burden (MRI-identified prostate imaging reporting and data system 4 or 5 lesions) simultaneously escalated to 42.5 to 45 Gy and areas overlapping organs at risk (within 2 mm of urethra, rectum, and bladder) constrained to 36.25 Gy (n = 100). Patients without a pretreatment MRI or without MRI-identified lesions were treated to dose of 37.5 Gy with no focal boost (n = 14). From 2015 to 2022, a total of 114 patients were enrolled with a median follow-up of 42 months. No acute or late grade 3+ gastrointestinal (GI) toxicity was observed. One patient developed late grade 3 genitourinary (GU) toxicity at 16 months. In patients treated with focal boost (n = 100), acute grade 2 GU and GI toxicity was seen in 38% and 4% of patients, respectively. Cumulative late grade 2+ GU and GI toxicities at 24 months were 13% and 5% respectively. Patient-reported outcomes showed no significant long-term change from baseline in urinary, bowel, hormonal, or sexual quality-of-life scores after treatment. SBRT to a dose of 40 Gy to the prostate gland with a simultaneous focal boost up to 45 Gy is well tolerated with similar rates of acute and late grade 2+ GI and GU toxicity as seen in other SBRT regimens without intraprostatic boost. Moreover, no significant long-term changes were seen in patient-reported urinary, bowel, or sexual outcomes from pretreatment baseline." @default.
• W4376130112 created "2023-05-12" @default.
• W4376130112 creator A5010414750 @default.
• W4376130112 creator A5021533197 @default.
• W4376130112 creator A5023442242 @default.
• W4376130112 creator A5028650860 @default.
• W4376130112 creator A5041234276 @default.
• W4376130112 creator A5041712330 @default.
• W4376130112 creator A5043943651 @default.
• W4376130112 creator A5060115400 @default.
• W4376130112 creator A5066273852 @default.
• W4376130112 creator A5070133098 @default.
• W4376130112 creator A5073499506 @default.
• W4376130112 creator A5083576766 @default.
• W4376130112 creator A5085109538 @default.
• W4376130112 creator A5086550454 @default.
• W4376130112 date "2023-05-01" @default.
• W4376130112 modified "2023-10-16" @default.
• W4376130112 title "Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging–Identified Prostate Cancer Lesions: Results of a Phase 2 Trial" @default.
• W4376130112 cites W1973462147 @default.
• W4376130112 cites W1977733462 @default.
• W4376130112 cites W1978906140 @default.
• W4376130112 cites W1997459378 @default.
• W4376130112 cites W2002612178 @default.
• W4376130112 cites W2008090769 @default.
• W4376130112 cites W2027570282 @default.
• W4376130112 cites W2054633472 @default.
• W4376130112 cites W2066705793 @default.
• W4376130112 cites W2100143139 @default.
• W4376130112 cites W2103290459 @default.
• W4376130112 cites W2104631398 @default.
• W4376130112 cites W2111180711 @default.
• W4376130112 cites W2117792530 @default.
• W4376130112 cites W2127644635 @default.
• W4376130112 cites W2127707619 @default.
• W4376130112 cites W2141944007 @default.
• W4376130112 cites W2157634805 @default.
• W4376130112 cites W2165244734 @default.
• W4376130112 cites W2167080855 @default.
• W4376130112 cites W2337386322 @default.
• W4376130112 cites W2465092116 @default.
• W4376130112 cites W2603384438 @default.
• W4376130112 cites W2736966846 @default.
• W4376130112 cites W2772705486 @default.
• W4376130112 cites W2803358834 @default.
• W4376130112 cites W2914880936 @default.
• W4376130112 cites W2952903287 @default.
• W4376130112 cites W3002858853 @default.
• W4376130112 cites W3014131856 @default.
• W4376130112 cites W3022703245 @default.
• W4376130112 cites W3125222626 @default.
• W4376130112 cites W3127066344 @default.
• W4376130112 cites W4200533807 @default.
• W4376130112 cites W4224236617 @default.
• W4376130112 cites W4295838570 @default.
• W4376130112 cites W4311201305 @default.
• W4376130112 cites W4312054062 @default.
• W4376130112 doi "https://doi.org/10.1016/j.ijrobp.2023.05.004" @default.
• W4376130112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37179035" @default.
• W4376130112 hasPublicationYear "2023" @default.
• W4376130112 type Work @default.
• W4376130112 citedByCount "0" @default.
• W4376130112 crossrefType "journal-article" @default.
• W4376130112 hasAuthorship W4376130112A5010414750 @default.
• W4376130112 hasAuthorship W4376130112A5021533197 @default.
• W4376130112 hasAuthorship W4376130112A5023442242 @default.
• W4376130112 hasAuthorship W4376130112A5028650860 @default.
• W4376130112 hasAuthorship W4376130112A5041234276 @default.
• W4376130112 hasAuthorship W4376130112A5041712330 @default.
• W4376130112 hasAuthorship W4376130112A5043943651 @default.
• W4376130112 hasAuthorship W4376130112A5060115400 @default.
• W4376130112 hasAuthorship W4376130112A5066273852 @default.
• W4376130112 hasAuthorship W4376130112A5070133098 @default.
• W4376130112 hasAuthorship W4376130112A5073499506 @default.
• W4376130112 hasAuthorship W4376130112A5083576766 @default.
• W4376130112 hasAuthorship W4376130112A5085109538 @default.
• W4376130112 hasAuthorship W4376130112A5086550454 @default.
• W4376130112 hasConcept C121608353 @default.
• W4376130112 hasConcept C126322002 @default.
• W4376130112 hasConcept C126838900 @default.
• W4376130112 hasConcept C126894567 @default.
• W4376130112 hasConcept C133507102 @default.
• W4376130112 hasConcept C143409427 @default.
• W4376130112 hasConcept C2776235491 @default.
• W4376130112 hasConcept C2780192828 @default.
• W4376130112 hasConcept C2781074409 @default.
• W4376130112 hasConcept C29730261 @default.
• W4376130112 hasConcept C509974204 @default.
• W4376130112 hasConcept C71924100 @default.
• W4376130112 hasConceptScore W4376130112C121608353 @default.
• W4376130112 hasConceptScore W4376130112C126322002 @default.
• W4376130112 hasConceptScore W4376130112C126838900 @default.
• W4376130112 hasConceptScore W4376130112C126894567 @default.
• W4376130112 hasConceptScore W4376130112C133507102 @default.
• W4376130112 hasConceptScore W4376130112C143409427 @default.
• W4376130112 hasConceptScore W4376130112C2776235491 @default.
• W4376130112 hasConceptScore W4376130112C2780192828 @default.
• W4376130112 hasConceptScore W4376130112C2781074409 @default.
• W4376130112 hasConceptScore W4376130112C29730261 @default.
• W4376130112 hasConceptScore W4376130112C509974204 @default.

• next